Analyst: Chinese reforms will impact sales and earnings at Novo Nordisk
Chinese healthcare reforms, meant to reduce healthcare expenses, could negatively affect Novo Nordisk, assesses Jyske Bank analyst, lowering forecasts for the company's revenue and earnings.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
Danish Jyske Bank reduces its 2022 revenue and earnings estimates for Novo Nordisk by a respective 3.1 and 4.8 percent as a consequence of China's healthcare reform efforts to keep costs down, writes Chief Analyst at Jyske Bank Henrik Hallengreen Laustsen. The analyst has the recommendation "hold" with a share price target of DKK 645 for Novo Nordisk.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
.jpg)
